Clinical Trial Update: Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the KRAS G12D-targeting agent RMC-9805 is currently recruiting for multiple solid tumor indications including non-small cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• RMC-9805 (RMC-9805)

Snippet

Sponsor: Revolution Medicines, Inc. | Conditions: Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) | Phase 1 | Status: RECRUITING